Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and XELOX in Metastatic Colorectal Cancer
NCT04008511Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Jul 2019
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in metastatic colorectal cancer (mCRC), sponsored by China Medical University. Status: unknown.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04008511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008511.